Financial reports
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
23 Apr 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
ImmunityBio Announces $320 Million Investment by Oberland
2 Jan 24
8-K
ImmunityBio Announces $470 Million Equity and Debt Financing
11 Sep 23
8-K
Other Events
1 Sep 23
8-K
Other Events
15 Aug 23
8-K
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
21 Jul 23
8-K
Other Events
20 Jul 23
8-K
Entry into a Material Definitive Agreement
14 Jun 23
8-K
Other Events
11 May 23
Registration and prospectus
S-3ASR
Automatic shelf registration
17 Apr 24
S-3
Shelf registration
28 Mar 24
D
$469.99 mm in equity / debt, sold $469.99 mm, 3 investors
22 Sep 23
424B5
Prospectus supplement for primary offering
25 Jul 23
424B5
Prospectus supplement for primary offering
24 Jul 23
424B5
Prospectus supplement for primary offering
15 Feb 23
S-3
Shelf registration
6 Feb 23
424B5
Prospectus supplement for primary offering
12 Dec 22
S-3MEF
Registration of additional securities for an S-3
12 Dec 22
424B5
Prospectus supplement for primary offering
12 Dec 22
Proxies
DEF 14C
Information statement
28 Sep 23
PRE 14C
Preliminary information
15 Sep 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEF 14C
Information statement
11 Jan 22
PRE 14C
Preliminary information
29 Dec 21
DEF 14A
Definitive proxy
29 Apr 21
DEFM14A
Proxy related to merger
2 Feb 21
Other
EFFECT
Notice of effectiveness
10 Feb 23
CORRESP
Correspondence with SEC
8 Feb 23
UPLOAD
Letter from SEC
8 Feb 23
UPLOAD
Letter from SEC
11 Jan 23
CORRESP
Correspondence with SEC
5 Jan 23
UPLOAD
Letter from SEC
20 Dec 22
EFFECT
Notice of effectiveness
19 May 22
EFFECT
Notice of effectiveness
27 May 21
EFFECT
Notice of effectiveness
2 Feb 21
EFFECT
Notice of effectiveness
4 Sep 19